Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Helex
Bengaluru, Karnataka, Indiahelex.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Helex is a biotechnology company developing next-generation CRISPR-based gene editing therapies for rare genetic and metabolic diseases. The company's proprietary platform focuses on creating one-time curative treatments by precisely modifying disease-causing genes within the body. Its lead programs target Primary Hyperoxaluria Type 1 (PH1), aiming to reduce toxic metabolite accumulation by silencing key enzymes such as Hydroxyacid oxidase 1. Based in Bengaluru, Helex leverages advanced genome engineering to address significant unmet medical needs in inherited disorders. The company has received backing from prominent global accelerators and venture firms, including SOSV and IndieBio.
- Therapeutic areas
- Rare Diseases
- Modalities
- CRISPR-based therapyGene therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Helex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helex.